Clinical Trials Logo

Cerebral Adrenoleukodystrophy clinical trials

View clinical trials related to Cerebral Adrenoleukodystrophy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02410239 Withdrawn - Clinical trials for Cerebral Adrenoleukodystrophy

MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).